RxDoctor Payments DataLook up a doctor →

Melinda Clark

Acute Care · Starkville, MSNPI 1285910653

Payments from drug & device makers

$13,768in general payments, 2019–2025

Across 649 payments — averaging $21.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$1K
  • E.r. Squibb & Sons, L.L.C.$1K
  • Incyte Corporation$894
  • Merck$778
  • Pfizer$710
  • Amgen$657
  • plus $8K from 54 others

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novartis66$1,186
E.r. Squibb & Sons, L.L.C.54$1,053
Incyte Corporation35$894
Merck37$778
Pfizer33$710
Amgen29$657
Daiichi Sankyo Inc.29$589
Johnson & Johnson26$588
Bristol Myers Squibb25$529
Gilead(2 entities)23$472
AstraZeneca(2 entities)16$438
Takeda Pharmaceuticals U.S.A., Inc.16$420
Regeneron Healthcare Solutions, Inc.14$305
GSK15$287
Pharmacyclics LLC, An Abbvie Company11$248
Puma Biotechnology, Inc.16$245
Sanofi12$236
Beigene USA, Inc.10$231
Eisai Inc.13$229
Rigel Pharmaceuticals, Inc.11$214
Adaptive Biotechnologies Corporation8$197
Apellis Pharmaceuticals, Inc.3$184
Lilly USA, LLC9$183
Bayer9$170
Taiho Oncology, Inc.8$155
Tersera Therapeutics LLC6$153
Boehringer Ingelheim6$135
Pharmacosmos Therapeutics Inc.7$131
AbbVie7$129
EMD Serono, Inc.6$127
Exelixis Inc.7$124
Sanofi-aventis U.S. LLC3$117
Seagen Inc.7$111
Jazz Pharmaceuticals Inc.4$105
Genmab U.S., Inc.5$101
Myriad Genetic Laboratories, Inc.2$99
Astellas Pharma US Inc5$96
Array Biopharma Inc4$81
Stemline Therapeutics Inc.4$79
Boston Scientific2$75
Karyopharm Therapeutics Inc.3$73
Ipsen Biopharmaceuticals, Inc3$73
Beone Medicines USA, Inc.3$64
Deciphera Pharmaceuticals Inc.3$62
Servier Pharmaceuticals LLC3$59
G1 Therapeutics, Inc.4$56
Blueprint Medicines Corporation3$51
Sobi, Inc2$41
Fennec Pharmaceuticals, Inc.2$38
Caris MPI, Inc.2$35
Geron Corporation2$34
Dendreon Pharmaceuticals LLC1$33
Secura Bio, Inc.2$32
Morphosys, US Inc.2$32
Pharmaessentia USA Corporation1$27
Mirati Therapeutics, Inc.1$25
Genentech USA, Inc.1$25
Tempus AI, Inc1$22
Coherus Oncology, Inc.1$22
Global Blood Therapeutics, Inc.1$19

How this compares

$13,768 in reported general payments places this provider in the 95th percentile of 223 acute care providers in Mississippi.

See all acute care providers in Mississippi →

Medicare billing

Part B allowed, 2024
$55,502
Medicare patients
448
Services billed
759

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other acute care in Starkville

See the full list for Mississippi →

Where these figures come from

Is this you, or does something look wrong? →